Search

Search results

2993 results found

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.

Gordon, Kenneth B, Kim A Papp, Richard G Langley, Vincent Ho, Alexa B Kimball, Cynthia Guzzo, Newman Yeilding, et al. 2012. “Long-Term Safety Experience of Ustekinumab in Patients With Moderate to Severe Psoriasis (Part II of II): Results from Analyses of Infections and Malignancy from Pooled Phase II and III Clinical Trials.”. Journal of the American Academy of Dermatology 66 (5): 742-51.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball, Alexa B, Arielle G Bensimon, Annie Guérin, Andrew P Yu, Eric Q Wu, Martin M Okun, Yanjun Bao, Shiraz R Gupta, and Parvez M Mulani. 2011. “Efficacy and Safety of Adalimumab Among Patients With Moderate to Severe Psoriasis With Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.”. American Journal of Clinical Dermatology 12 (1): 51-62.

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).

Kimball, A B, C Leonardi, M Stahle, W Gulliver, M Chevrier, S Fakharzadeh, K Goyal, et al. 2014. “Demography, Baseline Disease Characteristics and Treatment History of Patients With Psoriasis Enrolled in a Multicentre, Prospective, Disease-Based Registry (PSOLAR).”. The British Journal of Dermatology 171 (1): 137-47.